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Abstract
Background: Glutathione transferases (GSTs) belong to the family of Phase II detoxification
enzymes. GSTs catalyze the conjugation of glutathione to different endogenous and exogenous
electrophilic compounds. Over-expression of GSTs was demonstrated in a number of different
human cancer cells. It has been found that the resistance to many anticancer chemotherapeutics is
directly correlated with the over-expression of GSTs. Therefore, it appears to be important to find
new GST inhibitors to prevent the resistance of cells to anticancer drugs. In order to search for
glutathione transferase (GST) inhibitors, a novel method was designed.
Results: Our results showed that two fragments of GST, named F1 peptide (GYWKIKGLV) and
F2 peptide (KWRNKKFELGLEFPNL), can significantly inhibit the GST activity. When these two
fragments were compared with several known potent GST inhibitors, the order of inhibition
efficiency (measured in reactions with 2,4-dinitrochlorobenzene (CDNB) and glutathione as
substrates) was determined as follows: tannic acid > cibacron blue > F2 peptide > hematin > F1
peptide > ethacrynic acid. Moreover, the F1 peptide appeared to be a noncompetitive inhibitor of
the GST-catalyzed reaction, while the F2 peptide was determined as a competitive inhibitor of this
reaction.
Conclusion: It appears that the F2 peptide can be used as a new potent specific GST inhibitor. It
is proposed that the novel method, described in this report, might be useful for screening the
inhibitors of not only GST but also other enzymes.
Background
Glutathione transferase (GST) (EC 2.5.1.18) is a multi-
functional enzyme, which protects cells against cytotoxic
and genotoxic stresses. GST catalyzes the conjugation of
cytotoxic agents to glutathione (γ-glutamyl-cysteinyl-gly-
cine), producing less reactive chemical species. Changes
in GST levels have been found to correlate with resistance
to anticancer drugs through accelerated detoxification of
these drugs' substrates [1-4].
Members of the GST family are present at relatively high
concentrations in the cytosol of various mammalian tis-
sues. Over-expression of GST isozymes has been reported
in a number of different human cancers, when compared
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increase in GST activity was found in lymphocytes from
chronic lymphocytic leukemia (CLL) patients, who were
resistant to chlorambucil, relative to lymphocytes from
untreated CLL patients [7]. As GST isozymes are fre-
quently up-regulated in many solid tumors and lympho-
mas, inhibition GST activity has become a new drug
design concept [8-13]. These facts led to the search for and
design of GST inhibitors, including their synthetic ana-
logues and glutathione conjugates, however, most of the
existing inhibitors are either too toxic to be used in vivo or
are effective only in vitro [14,15].
Although several different GST inhibitors have been
reported, to our knowledge, there are no reports on design
of the GST inhibitors according to GST sequence. In this
report, a novel, covering all gene fragments (CAGF), clon-
ing method was used to screen the GST fragments which
can bind to glutathione and form the inhibitory com-
plexes. These inhibitory complexes act as modified sub-
strate inhibitors or substrate homologues to inhibit the
GST activity. The method described in this report should
be suitable not only for development of novel drugs
inhibiting the GST activity, but also for finding effective
inhibitors in other enzyme-catalyzed reaction systems.
Results
Screening the GST inhibitors using the fragments of GST
The scheme of the 'covering all gene fragments' (CAGF)
cloning method is shown in Fig. 1, and the whole screen-
ing procedure is shown in Fig. 2. Following five-time pan-
ning procedure, as described in the Methods section, 150
positive clones, which can tightly bind to the glutathione
Sepharose 4B beads, were picked up from the plates. The
typical panning efficiency during each round is shown in
Table 1. After five-time panning procedure, the fraction of
unbound E. coli cells was significantly decreased, from
about 11% to 3.9 × 10-5%.
The 150 positive clones were picked up from the plates
and used for screening the GST inhibitors. Following five
consecutive screening procedures (consisting of screening
the binding of peptides to glutathione Sepharose 4B
beads, and screening the positive clones as GST inhibi-
tors), the inhibitor efficiencies of all positive clones were
compared. We found that positive clones expressing
GYWKIKGLV (F1 peptide) and KWRNKKFELGLEFPNL
(F2 peptide) can significantly inhibit GST activity. The
binding efficiency of E. coli cells expressing F1 or F2 pep-
tides on the glutathione Sepharose 4B beads was con-
firmed by an independent experiment. The fraction of E.
coli cells expressing F1 or F2 peptides unbound to the glu-
tathione Sepharose 4B beads was 2.3 × 10-5% or 1.1 × 10-
5%, respectively, while 26.4% control E. coli cells
remained unbound to such beads (Table 2).
It has been concluded from the crystallographic study that
Arg41, Lys44 and Asn53 of GST can interact with glutathione
[16]. Here, our results show that the identified F2 peptide
KWRNKKFELGLEFPNL contains Arg41, Lys44 and Asn53
(indicated in bold letters). The control peptide F4, lacking
Arg41, Lys44 and Asn53 residues, could not bind efficiently
to the glutathione Sepharose 4B beads (Table 3). Moreo-
ver, Tyr6, Trp7 and Leu12 of GST were shown to interact
with glutathione [16], and our results show that F1 pep-
tide GYWKIKGLV contains Tyr6, Trp7 and Leu12 (indicated
in bold letters). Moreover, the control peptide F3, lacking
Tyr6, Trp7 and Leu12,could not bind efficiently to glutath-
ione Sepharose 4B beads (Table 3).
Results of the screening with the use of the CAGF cloning
method are consistent with the crystallographic data. The
structure-function analysis has shown that GST contains
one important binding site (G-site) for glutathione [1].
Experiments based on kinetic and chemical modification
techniques indicated that the active site might contain
either His, Cys, Trp, Arg, or Asp [17-21]. The crystal struc-
ture indicates that GST binds two molecules of glutath-
ione sulfonate at the G-site. Several groups have
investigated changes in amino acids involved in the for-
mation of the G site of GST. The Tyr6, as one of the impor-
tant components of the G site, is conserved in many
mammalian GSTs. Tyr6 plays an essential role in stabiliz-
ing the thiolate anion of glutathione through hydrogen
bonding. This residue was studied using site-directed
mutagenesis, and when Tyr was replaced by different
amino acids, GST has lost at least 90% its specific activity
[22-24]. Our results with the CAGF cloning method also
suggest an important function of Tyr6 in glutathione bind-
Table 1: The binding efficiency of E. coli cells after each round of panning procedure on glutathione Sepharose 4B beads.
E. coli cells Panning round Input E. coli cells Unbound E. coli cells Elution efficiency (%)
E. coli cell expressing GST fragments 1 3.8×1010 4.2×109 11.05
2 4.2×1010 5.8×107 0.14
3 4.8×1010 5.1×106 1.1×10-2
4 5.6×1010 6.5×105 1.2×10-3
5 6.9×1010 2.7×104 3.9×10-5Page 2 of 11
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crystallographic data.
The binding characteristics of F1 and F2 peptides
To determine the binding characteristics of selected pep-
tides (F1 and F2), an analysis of the interaction of synthe-
sized peptides with glutathione Sepharose 4B beads was
performed using the Scatchard method. The Scatchard
analysis is a method of linearizing data from the binding
experiment in order to determine binding capacity. The
ratio of specific binding and free concentrations was plot-
ted against specific binding concentration. The maximum
binding capacity Bmax and dissociation constant Kd of F1
and F2 peptides were determined. Our results show that
there are about 1.1 F1 peptide and 1.2 F2 peptide binding
sites on glutathione Sepharose 4B beads, and the disasso-
ciation constant of the F2 peptide is lover than that of the
F1 peptide (Table 4).
The binding efficiencies of F1-glutathione and F2-glutath-
ione to GST were further confirmed by analysis of the
binding of GST to the F1 peptide-glutathione Sepharose
4B complex and the F2 peptide-glutathione Sepharose 4B
complex. The appropriate binding capacity Bmax and dis-
sociation constant Kd values were determined. The results
show that there are about 1.2 GST binding sites for F1
peptide-glutathione Sepharose 4B complex, and 1.5 GST
binding sites for F2 peptide-glutathione Sepharose 4B
complex. The disassociation constant of GST on F2 pep-
tide-glutathione Sepharose 4B complex was lower than
that of GST on F1 peptide-glutathione Sepharose 4B com-
plex (Table 5).
Cloning all GST gene fragments into the plasmid DNA vector with the covering all gene fragments (CAGF) cloning m th dFigure 1
Cloning all GST gene fragments into the plasmid 
DNA vector with the covering all gene fragments 
(CAGF) cloning method. A): The gene fragments of GST, 
B): The amplification of GST fragments using the system con-
taining ddNTP, which can terminate the amplification reac-
tion, and produce the DNA sequences with the single base 
differences, thus, the reaction system can produce a large 
library of fragments with single base differences. C): The 
binding of amplified products, D): Digestion of the CAGF 
cloning products with Exonuclease VII to form the blunt-
ended DNA fragments. E): Amplification of the whole pFliTrx 
plasmid with the primers FP2 and RP2, F): The linearized pFil-
Trx plasmid was linked with the DNA library of the gene 
encoding GST.
The experimental procedure for screening the fragments of GST which ca  significantly inhibit GST activityFigure 2
The experimental procedure for screening the frag-
ments of GST which can significantly inhibit GST 
activity.Page 3 of 11
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The synthesized peptides F1 and F2 were used in the anal-
ysis of the efficiency of inhibition of GST activity (Table
6). The inhibition efficiencies were as follows: tannic acid
> cibacron blue > F2 peptide > hematin > F1 peptide >
ethacrynic acid, with the use of CDNB or DCNB as the
substrates. Moreover, we could not find any significant
inhibition of the GST activity using control peptides F3 or
F4.
These results indicate that we have found an efficient GST
inhibitor, the F2 peptide, which is more efficient than
hematin (35.2% activity with CDNB as a substrate, 42.1%
activity with DCNB as a substrate). We also found another
inhibitor of this reaction, the F1 peptide, which is more
efficient than ethacrynic acid (55.1% activity with CDNB
as a substrate, 81.2% activity with DCNB as a substrate).
The inhibition characteristics of selected peptides
The inhibitory effects of selected F1 and F2 peptides on
the GST-catalyzed reaction, using CDNB and glutathione
as substrates, are shown in Fig. 3. Peptides F1 and F2
inhibited the reaction in a dose-dependent manner, with
50% inhibitory concentrations of 0.8 μM and 0.6 μM,
respectively.
To obtain information on the nature of the inhibition by
F1 and F2 peptides, GST activity was measured with vari-
able concentrations of glutathione. Here, we applied a
new model in describing enzyme inhibitor (Fig. 4). It is
possible that when the F1 or F2 peptide bound to the sub-
strate glutathione, a peptide-glutathione complex was
formed. Because the concentration of the peptide inhibi-
tor was significantly lower than the substrate (glutath-
ione) concentration, we assumed that the binding of the
peptide inhibitor with glutathione will not significantly
affect the substrate concentration. Hence, the newly
formed peptide-glutathione complex was considered as a
new inhibitor. The concentration of the peptide-glutath-
ione inhibitor is almost equal to the peptide concentra-
tion, thus, the Michaelis-Menten equation was used in the
analysis.
The Lineweaver-Burk plot for glutathione as the variable
peptide concentration was applied to determine the types
of inhibition caused by F1 and F2 peptides. The plot pro-
vides a useful graphical method for analysis of the
Michaelis-Menten equation. The effects of the peptide on
GST-catalyzed reaction kinetics were determined by anal-
ysis of apparent Vmax, inhibitor constant Ki and [I]/Ki val-
ues. Our results indicated that the F1 peptide exerted a
noncompetitive inhibition in the GST-catalyzed reaction
with the changing glutathione and F1 peptide concentra-
tions (Vmax decreased while Km remained unchanged)
(Fig. 5A). However, the F2 peptide exerted a competitive
inhibition in this reaction, with the changing glutathione
and F2 peptide concentrations (Km decreased while Vmax
remained unchanged) (Fig. 5B).
The Vmax, Ki and [I]/Ki values for the F1 peptide were deter-
mined (Table 7). The Vmax value of the GST-catalyzed reac-
tion was determined as 1 μmol/mg/min. However, in the
presence of 0.8 μM F1 peptide inhibitor, the Vmax, Ki and
[I]/Ki values were determined as 0.833 μmol/mg/min, 4.0μM and 0.2, respectively. With the increasing F1 peptide
concentrations, from 0.8 to 3.2 μM, the Vmax value
decreased from 0.833 μmol/mg/min to 0.645 μmol/mg/
min, Ki value increased from 4.0 μM to 5.82 μM, and [I]/
Ki value increased from 0.2 to 0.55.
The Km, Ki and [I]/Ki values for the F2 peptide were also
determined (Table 8). The Km value of the GST-catalyzed
reaction was determined as 0.25 mM. However, in the
presence of 0.8 μM F2 peptide inhibitor, the Km, Ki and
[I]/Ki values were determined as 0.38 mM, 1.53 μM and
0.52, respectively. With the increasing F2 peptide concen-
trations from 0.8 to 3.2 μM, the Km value increased from
0.38 mM to 0.58 mM, Ki value increased from 1.53 μM to
2.42 μM, and [I]/Ki value increased from 0.52 to 1.32.
Table 2: The binding efficiency of E. coli cells expressing F1 and F2 peptides on glutathione Sepharose 4B beads.
E. coli cells Input E. coli cells Unbound E. coli cells Elution efficiency (%)
E. coli cells expressing F1 peptide 3.0×1010 6.8×104 2.3×10-5
E. coli cells expressing F2 peptide 2.8×1010 3.2×104 1.1×10-5
E. coli cells (control) 3.6×1010 9.5×109 26.4
Table 3: The binding of synthesized peptides F1, F2, F3 and F4 to 
glutathione Sepharose 4B beads.
Peptide Binding efficiency
Before elution After elution
F1 99.6% 2.1%
F2 99.3% 1.8%
F3 1.2% 1.2%
F4 2.6% 2.5%
The binding efficiencies of different peptides were determined 
according to the ratio of peptide concentrations after the binding and 
before the binding experiments. Moreover, the peptide binding 
characteristics were determined again, after the peptides were eluted 
with the elution buffer.Page 4 of 11
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DCNB, from 0.5 mM to 2 mM, the kinetics of the GST-cat-
alyzed reaction remained similar in the reaction system
containing GST, glutathione and the inhibitor (F1 peptide
or F2 peptide). Therefore, we conclude that CDNB and
DCNB cannot significantly affect the inhibition efficiency
of F1 peptide or F2 peptide.
All these results show that effective non-competitive
inhibitor F1 peptide and competitive inhibitor F2 peptide
were found by using the CAGF cloning method. Although
F1 and F2 peptides comprise only a small part of GST,
they show significant inhibition efficiencies in the GST-
catalyzed reaction.
Discussion
The development of resistance to anticancer agents is a
primary concern in cancer chemotherapy. In this light, it
is obvious that the emergence of drugs, such as the GST
inhibitors, able to overcome this resistance is a advance-
ment [10,11]. Therefore, it is of special interest to develop
GST inhibitors able to enhance the therapeutic index of
anticancer drugs. Ethacrynic acid and quinine, which are
both GST inhibitors, have been reported to reverse the
resistance to melphalan and doxorubicin of cancer cell
lines with increased GST expression [25]. In fact,
ethacrynic acid has been used as an inhibitor of GST in
vivo. However, first-generation GST inhibitors (e.g.
ethacrynic acid) were unsuccessful in clinical trials. This
might be due to its lack of specific function for GST iso-
zyme, and propensity to react with other chemicals. In
addition, there caused a number of unwanted clinical side
effects. Therefore, more specific GST inhibitors may elim-
inate some of these undesirable features.
Here, we used the CAGF cloning method to find the GST
fragments interacting with glutathione, which might be
useful for the finding of GST inhibitors. We found two
inhibitory peptide fragments, F1 peptide and F2 peptide.
Our results revealed that F2 peptide is a potent inhibitor
of the reaction with IC50 of 0.6 μM (Fig. 3).
The putative inhibition mechanisms of actions of F1 and
F2 peptide inhibitors are shown in Fig. 4. The F1-glutath-
ione complex was found to be a non-competitive inhibi-
tor, suggesting that the inhibitory binding site of F1-
glutathione is different from the catalytic site of GST. An
analysis of the crystal structure of GST and glutathione
shows that the F1 peptide is located in the interior posi-
tion of the G site (Fig. 6A). It may be difficult for F1-glu-
tathione complex to dock into the catalytic site of GST. We
assume that F1-glutathione complex may be docked into
non-catalytic site of GST, affect the structure of catalytic
site of GST, and cause the non-competitive inhibition.
On the other hand, the F2 peptide is located in the mar-
ginal position of the G site of GST (Fig. 6B). It may be easy
for F2-glutathione complex to duck into the catalytic site
of GST. We assume that the F2-glutathione complex may
be docked into the G site of GST. Thus, F2-glutathione
may directly interfere with the catalytic site of GST and
glutathione. Since the F2-glutathione causes a competitive
inhibition, the F2 peptide may be a good candidate for
further studies on cancer chemomodulation.
Table 4: The binding of F1 and F2 peptides to glutathione.
Peptide Binding characteristics of peptides on glutathione Sepharose 4B beads
Bmax (site) Kd (pM)
F1 peptide 1.1 45.6
F2 peptide 1.2 18.3
The experiments were performed according to the binding characteristics of F1 and F2 peptides to the glutathione Sepharose 4B beads. The 
concentrations of bound and free peptides were determined following separation of the binding complexes by centrifugation, and the free peptide 
concentration in the supernatant was detected by the Lowry method.
Table 5: The binding of F1 and F2 peptides to GST.
Peptide-glutathione Sepharose 4B beads Binding characteristics of GST on peptide-glutathione Sepharose 4B beads
Bmax (site) Kd (pM)
F1 peptide-glutathione Sepharose 4B beads 1.2 156.3
F2 peptide-glutathione Sepharose 4B beads 1.5 114.2
The experiments were performed according to the binding characteristics of GST with F1 peptide-glutathione Sepharose 4B bead complex and F2 
peptide-glutathione Sepharose 4B bead complex. The concentrations of bound and free GST were determined after separation of complexes by 
centrifugation, and the free GST concentration in the supernatant was determined by the Lowry method.Page 5 of 11
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tory activity of GST fragment-substrate complexes on GST-
catalyzed reaction. When the F1 or F2 peptide bound to
the substrate glutathione, a peptide-glutathione complex
was formed. Although GST can convert glutathione into
the reaction products, this enzyme cannot convert the
peptide-glutathione inhibitor into the product. Thus, the
binding of the peptide-glutathione to GST can inactive the
enzyme activity. We speculate that peptide-glutathione
occupied the functional domain or affected the functional
domain of GST. Thus, GST-peptide-glutathione or GST-
glutathione-peptide complex cannot catalyze the conver-
sion of glutathione (Fig 4B and 4C). Here, the function of
peptide-glutathione inhibitor is just like the substrate
homologue or substrate-modifying inhibitor [26].
In summary, we have determined two glutathione-bind-
ing fragments of the GST sequence, and found that the F2
peptide, selected by the CAGF cloning method, can be
considered as the inhibitor of GST. The F2 peptide is a
potent inhibitor, stronger than hematin and ethacrynic
acid, but weaker than tannic acid and cibacron blue. We
suggest that the F2 peptide can be considered in applica-
tions against GST-induced multidrug resistance.
Moreover, Fig. 7 shows the scheme of the novel method
in finding enzyme inhibitors. In the first step, the enzyme
fragments which can bind with the substrate were
screened to find the binding peptides. In the second step,
the complexes of enzyme fragments and substrate were
screened to find the enzyme inhibitor. We believe that this
method can be used as a common tool for finding enzyme
fragments that interact with a substrate, and subsequently
for finding enzyme inhibitors.
Table 6: Effects of different inhibitors (two selected peptides F1 
and F2, tannic acid, cibacron blue, hematin, and ethacrynic) on 
the GST activity.
Inhibitor (1 μM) Specific GST activity (units/mg)
CDNB (1 mM) DCNB (1 mM)
Control 2.80 ± 0.01 (100%) 4.51 ± 0.02 (100%)
F1 1.20 ± 0.01(43.1%) 2.65 ± 0.02 (58.8)
F2 0.73 ± 0.01 (26.1%) 1.49 ± 0.02 (33.2%)
tannic acid 0.16 ± 0.01 (5.6%) 0.49 ± 0.01 (10.9%)
cibacron blue 0.51 ± 0.01 (18.3%) 0.96 ± 0.01 (21.3%)
hematin 0.99 ± 0.01 (35.2%) 1.90 ± 0.02 (42.1%)
ethacrynic acid 1.54 ± 0.01 (55.1%) 3.66 ± 0.02 (81.2%)
Experiments were performed using glutathione and CDNB or DCNB 
as substrates. The activity was determined as described in the 
Methods section. Mean values ± SD for triplicate determinations are 
shown. A unit of GST activity was defined as the formation of 1 μmol 
of the product per min under the conditions of the specific assay. 
Specific activity is defined as the units of enzyme activity per mg of 
GST in the reaction system.
Effects of F1 and F2 peptides on the activity of GST (μmol/mg/min)Fi ure 3
Effects of F1 and F2 peptides on the activity of GST 
(μmol/mg/min). The activity was measured by monitoring 
the GST activity with different peptide concentrations, 1 mM 
glutathione (GSH) and 1 mM CDNB in 100 mM potassium 
phosphate buffer (pH6.5) at 25°C. Each point shows the 
mean ± SD of triplicate determinations. Relative GST activity 
was obtained from the ratio of GST activity in the presence 
of inhibitor and without inhibitor.
The putative mechanisms of F1 peptide- and F2 peptide-mediated nhibition of the GST activ tyFigure 4
The putative mechanisms of F1 peptide- and F2 pep-
tide-mediated inhibition of the GST activity. A): Bind-
ing of the enzyme (blue) and substrate (red) results in 
formation of the enzyme-substrate complex, and then in lib-
eration of the final product. B): Binding of the F1 peptide 
(black) and substrate (red) leads to formation of a new pep-
tide-substrate complex inhibitor, which may non-competi-
tively inhibit the enzyme activity. C): Binding of the F2 
peptide (green) and substrate (red) leads to formation of a 
new peptide-substrate complex inhibitor, which may com-
petitively inhibit the enzyme activity.Page 6 of 11
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In conclusion, we have successfully found a F2 peptide as
GST inhibitor with the novel screening method from GST
sequence. Our screening method should be useful for
screening many different enzyme inhibitors.
Methods
Generation of the GST library
The forward primer FP1: 5' ATG TCC CCT ATA CTA GGT
3' and reverse primer RP1: 5' TCA CGA TGC GGC CGC
TCG 3' were used to amplify the Schistosoma japonicum
full-length GST gene [27] from the pGEX4T-2 plasmid
DNA vector (Amersham). The amplified DNA fragments
were purified with the QIAquick PCR purification kit
(QIAGEN). The following reaction system was used: 1 ng
pGEX4T-2 plasmid, 50 mM Tris-HCl (pH 7.8), 5 mM
MgCl2, 10 mM 2-mercaptoethanol, 10 μg/ml BSA, 1 ng
forward primer FP1 and 1 ng reverse primer RP1, 20 μM
dNTP, 1 μM dideoxynucleotides (ddNTP), 2 units DNA
Polymerase I (Invitrogen), and ddH2O to the reaction vol-
ume of 100 μl; incubation at 15°C for 30 to 60 min.
The amplified DNA library was purified by using the phe-
nol-chloroform method, and dissolved in water. The DNA
library was digested with the Exonuclease VII (Epicentre),
which has a high enzymatic specificity for single-stranded
DNA and exhibits both 5' → 3' and 3' → 5' exonuclease
activities. This enzyme is especially useful for rapid
removal of single-stranded oligonucleotide primers.
Cloning the GST library into pFliTrx vector
The cloning of DNA library into the pFliTrx vector (Invit-
rogen) was performed as shown in Fig. 1. The pFliTrx was
amplified using Pfx DNA polymerase (Invitrogen) with
the forward primer FP2: 5' GGT CCG TCG AAA ATG ATC
GCC CCG ATT CTG GAT 3' and the reverse primer RP2: 5'
CGG ACC GCA CCA CTC TGC CCA GAA ATC GAC GAA
3'. The two-step PCR reaction was performed under the
following conditions: 92°C for 2 min; then 35 cycles at
68°C for 5 min, and 92°C for 30 s. The amplified PCR
product was purified by using the QIAquick PCR purifica-
tion kit (QIAGEN).
The purified PCR product of linearized pFliTrx (without
the fusion junction) was used to link it to the DNA library
Lineweaver-Burk plot of the GST activity with varying glu-tathione (GSH) concentrationsFigur  5
Lineweaver-Burk plot of the GST activity with vary-
ing glutathione (GSH) concentrations. A): The activity 
was measured with 1 mM CDNB, and different concentra-
tions of GSH, and the F1 peptide. B): The activity was meas-
ured with 1 mM CDNB, and different concentrations of 
GSH, and the F2 peptide.
Table 7: The characterization of the F1 peptide as an inhibitor of the GST-catalyzed reaction (The Vmax, Ki and [I]/Ki values of the 
GST-catalyzed reaction in the presence of the F1 inhibit peptide were determined).
F1 peptide concentration [I] (μM) Vmax value (μmol/mg/min) Ki value (μM) [I]/Ki
0 1.0 - -
0.8 0.833 4.0 0.2
1.6 0.741 4.57 0.35
3.2 0.645 5.82 0.55Page 7 of 11
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BMC Biochemistry 2009, 10:6 http://www.biomedcentral.com/1471-2091/10/6with T4 ligase. The ligation products were introduced into
the E. coli GI826 (F-, lacIq, ampC::Ptrp::cI, ΔfliC, ΔmotB,
eda::Tn10) (Invitrogen).
Screening the GST fragments which can bind to 
glutathione
The GST library was introduced to E. coli GI826 compe-
tent cells, which were then cultured in 50 ml of IMC
medium (1 × M9 salts, 0.2% casamino acid, 0.5% glucose,
1 mM MgCl2) containing 100 μg/ml ampicillin with shak-
ing (225–250 rpm) to saturation (OD600 = 3) for 15 hours
at 25°C. E. coli cells were added to 50 ml IMC medium
containing 100 μg/ml ampicillin and 100 μg/ml tryp-
tophan for induction. The cells were grown at 25°C with
shaking for 6 hours. Then, 1 ml of glutathione Sepharose
4B (Amersham) slurry and 1 ml of tryptophan-induced
culture broth were added to 40 ml of the PBS buffer in a
50 ml tube, and kept at the room temperature for 30 min,
centrifuged at 1,000 × g for 10 min at the room tempera-
ture, then resuspended in the PBS buffer, and centrifuged
at 1,000 × g for three more times. Finally, the pellet was
resuspended in 2 ml of PBS, and 500 μl of elution buffer
(50 mM Tris-HCl, 10 mM reduced glutathione, pH 8.0)
were added to elute the bound E. coli cells. The eluted E.
coli cells were used for the next panning procedure. Fol-
lowing the panning procedure, 100 μl of the eluted solu-
tion was added on the RMG plates (1 × M9 salt, 0.2%
casamino acid, 0.5% glucose, 1 mM MgCl2, 1.5% agar).
The plates contained 100 μg/ml ampicillin for selection of
the positive clones. Then the single positive clones from
the RMG plates were picked up, and 150 single clones
were used for screening the GST inhibitors.
Screening of GST fragments which can inhibit the GST 
activity
150 single positive clones (grown on the RGB plates), that
could tightly bind to the glutathione Sepharose 4B, were
picked up from the plates, and cultured separately in 50
ml of IMC medium containing 100 μg/ml ampicillin for
15 hours at 25°C, then induced with 100 μg/ml tryp-
tophan for 6 hours. E. coli cells were washed with the PBS
buffer for three times at 4°C, and suspended in the 5 ml
PBS solution, respectively.
Recombinant S. japonicum GST, glutathione, tannic acid,
cibacron blue, hematin, ethacrynic acid, 1,2-dichloro-4-
nitrobenzene (DCNB) and 2,4-dinitrochlorobenzene
(CDNB) were purchased from Sigma-Aldrich, and used to
measure the GST activity.
To measure the GST activity, glutathione and CDNB solu-
tions were added (to final concentration of 1 mM) to 100
μl of E. coli cell suspension (108 cells). Then, GST solution
was added (the cell suspension without glutathione was
used as the control). The GST activity was measured by
using the spectrophotometric assay [28].
The single clones, which can produce the GST inhibitory
peptide, were selected again, and the plasmid DNA was
extracted for determination of inserted sequences. The
whole screening procedures were performed five times.
Finally, plasmid DNAs were extracted from E. coli cells
expressing inhibitory peptides, and sequenced.
Analysis of the binding of peptides to glutathione
The binding characteristics of selected peptides to glutath-
ione were determined according to the analysis of binding
of synthesized peptides to the glutathione Sepharose 4B
beads. The amount of glutathione in the glutathione
Sepharose 4B beads was estimated according to the
assumption (according to the manufacturere's informa-
tion) that there are about 200–400 μmol glutathione/g
dried beads. An average value of 300 μmol glutathione/g
dried beads was used to calculate the amount of glutath-
ione in the glutathione Sepharose 4B beads. In our exper-
iments, appropriate amount of wet glutathione Sepharose
4B beads (equal to 1 mg dry beads) was added to a 1.5 ml
Eppendorf tube, and different amounts of synthesized
peptides were added into the tube. After binding for 10
min at 37°C, the binding complexes were separated by
centrifugation (12,000 × g for 10 min) and concentrations
of bound and free peptides were determined by using the
Lowry method [29]. Scatchard analysis was used to deter-
mine the Kd and Bmax values. Bmax means the maximum
binding sites of synthesized peptide on glutathione Spe-
harose 4B beads (μmol peptide/μmol glutathione). Kd is a
dissociation constant (pM). Thus, a low Kd value indicates
a high affinity.
Table 8: The characterization of the F2 peptide as an inhibitor of the GST-catalyzed reaction (The Vmax, Ki and [I]/Ki values of the 
GST-catalyzed reaction in the presence of the F2 inhibit peptide were determined).
F2 peptide concentration [I] (μM) Km value (mM) Ki value (μM) [I]/Ki
0 0.25 - -
0.8 0.38 1.53 0.52
1.6 0.50 1.60 1.0
3.2 0.58 2.42 1.32Page 8 of 11
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GST
The binding of selected peptide-glutathione complexes
with GST were determined on the basis of analysis of
binding of GST to the peptide-glutathione Sepharose 4B
bead complex. Wet glutathione Sepharose 4B beads
(equal to 1 mg dry wet) was added into a 1.5 ml Eppen-
dorf tube for binding to peptides. After the binding of
peptides to glutathione Sepharose 4B beads at 37°C for
10 min, the unbound peptides were washed out. Then,
different amounts of GST were added into the tube. After
binding for 10 min at 37°C and separation of the bound
complexes by centrifugation, the amounts of bound and
free GST were determined by the Lowry method [29].
Scatchard analysis was used to determine the Kd and Bmax
values. Bmax means the maximum binding site of GST with
the peptide on peptide-glutathione Speharose 4B beads
(μmol GST/μmol peptide-glutathione). Kd is a disassocia-
tion constant (pM).
The crystal structure of GST with putative binding sites of F1 peptide (A) and F2 peptide (B) inhibi orsFigur 6
The crystal structure of GST with putative binding 
sites of F1 peptide (A) and F2 peptide (B) inhibitors. 
Symbols: GST (purple), glutathione (brown), selected peptide 
(yellow). The crystal structure of GST and glutathione com-
plex was viewed using the protein structure data (PDB: 
1m99).
The scheme of the novel method for finding enzyme inhibi-torsFigure 7
The scheme of the novel method for finding enzyme 
inhibitors.Page 9 of 11
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When the screening experiments were performed, four
peptides were synthesized to analyze their inhibition effi-
ciencies. F1 peptide (GYWKIKGLV, yield: 25.3 mg), F2
peptide (KWRNKKFELGLEFPNL, yield: 28.1 mg), F3 pep-
tide (GKIKGV, yield: 2.2 mg) and F4 peptide (KWNKFEL-
GLEFPL, yield: 1.9 mg) were obtained from the Invitrogen
(Custom Peptide Synthesis, with the purity > 95%).
Recombinant S. japonicum GST (~40 units/mg), glutath-
ione, tannic acid, cibacron blue, hematin, ethacrynic acid,
1,2-dichloro-4-nitrobenzene (DCNB) and 2,4-dinitro-
chlorobenzene (CDNB) were from Sigma-Aldrich Co. The
inhibition studies were carried out according to the previ-
ously described method [28] at 25°C using glutathione (1
mM) and CDNB (1 mM) or DCNB (1 mM) as substrates.
The inhibitors (tannic acid, cibacron blue, hematin,
ethacrynic acid or the synthesized peptides) were added to
the reaction mixture and GST activity was determined.
The peptide concentration resulting in 50% inhibition
(IC50) was determined from a plot of remaining activity
versus peptide concentration. Protein concentration was
measured according to the Lowry method [29]. Enzyme
inhibitory kinetic studies were carried out using various
concentrations of glutathione and CDNB and different
concentrations of synthetic peptides (0.8, 1.6, 3.2 μM).
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